Zobrazeno 1 - 10
of 9 287
pro vyhledávání: ''
Autor:
Andrea De Giglio, Valeria Grandinetti, Marta Aprile, Greta Borelli, Anita Campus, Anna Laura Croci Chiocchini, Marco Busutti, Gisella Vischini, Alessandro Di Federico, Francesca Sperandi, Barbara Melotti, Andrea Ardizzoni, Gaetano La Manna, Francesco Gelsomino
Publikováno v:
Lung Cancer. 174:91-96
The combination of immune-checkpoint inhibitors (ICI) and platinum-pemetrexed chemotherapy (CT) in first-line setting improved survival outcomes of advanced non-small cell lung cancer (NSCLC) patients. Among the various adverse events, renal toxicity
Autor:
Tahani Atieh, Shebli Atrash, Nausheen Ahmed, Meera Mohan, Wei Cui, Leyla Shune, Susana Hajjar, Zahra Mahmoudjafari, Julie Quick, Anne Wishna, Justin Riffel, Joseph McGuirk, Ghulam Rehman Mohyuddin, Al-Ola Abdallah
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:912-919
Triple-class relapsed/refractory multiple myeloma (RRMM) has a poor prognosis. This study analyzed the clinical outcomes of Belantamab mafadotin in combination with dexamethasone (Bd) in triple-class RRMM.We identified 35 patients with triple-class R
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:835-840
Gemcitabine-based regimens are effective salvage therapy for RR lymphoma patients eligible for ASCT, but there is limited data in transplant-ineligible (TIE) patients. Here, we present a retrospective analysis on the outcome of TIE adult patients wit
Autor:
Seong Hyun, Jeong, Seok Jin, Kim, Dok Hyun, Yoon, Yong, Park, Hye Jin, Kang, Youngil, Koh, Gyeong-Won, Lee, Won-Sik, Lee, Deok-Hwan, Yang, Young Rok, Do, Min Kyoung, Kim, Kwai Han, Yoo, Yoon Seok, Choi, Hwan Jung, Yun, Jun Ho, Yi, Jae-Cheol, Jo, Hyeon-Seok, Eom, Jae-Yong, Kwak, Ho-Jin, Shin, Byeong Bae, Park, Shin Young, Hyun, Seong Yoon, Yi, Ji-Hyun, Kwon, Sung Yong, Oh, Hyo Jung, Kim, Byeong Seok, Sohn, Jong Ho, Won, Se-Hyung, Kim, Ho-Sup, Lee, Cheolwon, Suh, Won Seog, Kim
Publikováno v:
Cancer Research and Treatment. 54:1268-1277
PurposeFebrile neutropenia (FN) can cause suboptimal treatment and treatment-related mortality (TRM) in diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP). Mate
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:e938-e946
One key clinical challenge remains in how to sequence treatments in follicular lymphoma (FL). The chemoimmunotherapy rituximab cyclophosphamide, doxorubicin, vincristine (Oncovin), and prednisone (R-CHOP) has been a standard treatment option for two
Autor:
Janssen, J J W M, Löwenberg, B, Manz, M, Biemond, B J, Westerweel, P E, Klein, S K, Fehr, M, Sinnige, H A M, Efthymiou, A, Legdeur, M C J C, Pabst, T, Gregor, M, van der Poel, M W M, Deeren, D, Tick, L W, Jongen-Lavrencic, M, van Obbergh, F, Boersma, R S, de Weerdt, O, Chalandon, Y, Heim, D, Spertini, O, van Sluis, G, Graux, C, Stüssi, G, van Norden, Y, Ossenkoppele, G J
Publikováno v:
Janssen, J J W M, Löwenberg, B, Manz, M, Biemond, B J, Westerweel, P E, Klein, S K, Fehr, M, Sinnige, H A M, Efthymiou, A, Legdeur, M C J C, Pabst, T, Gregor, M, van der Poel, M W M, Deeren, D, Tick, L W, Jongen-Lavrencic, M, van Obbergh, F, Boersma, R S, de Weerdt, O, Chalandon, Y, Heim, D, Spertini, O, van Sluis, G, Graux, C, Stüssi, G, van Norden, Y & Ossenkoppele, G J 2022, ' Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome ', Leukemia, vol. 36, no. 9, pp. 2189-2195 . https://doi.org/10.1038/s41375-022-01657-3
Leukemia, 36(9), 2189-2195. Nature Publishing Group
Leukemia, Vol. 36, no.9, p. 2189-2195 (2022)
Leukemia, 36, 2189-2195. Nature Publishing Group
Leukemia, 36(9), 2189-2195. Nature Publishing Group
Leukemia, Vol. 36, no.9, p. 2189-2195 (2022)
Leukemia, 36, 2189-2195. Nature Publishing Group
Treatment results of AML in elderly patients are unsatisfactory. In an open label randomized phase II study, we investigated whether addition of the XPO1 inhibitor selinexor to intensive chemotherapy would improve outcome in this population. 102 AML
Autor:
Lalit Kumar, Mohammad Mir Hussain, Rajegowda Chethan, Ranjit Kumar Sahoo, Prabhat S. Malik, Om Dutt Sharma, Anisha Mathew, Ankit Jha, Ritu Gupta, Atul Sharma, Ahitagni Biswas, Rakesh Kumar, Sanjay Thulkar, Soumyaranjan Malik, Ashish Dutt
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:e826-e835
Autologous stem cell transplant (ASCT) is a standard therapy for transplant eligible patients of multiple myeloma (MM). To evaluate impact of time to transplant on subsequent outcomes, we analyzed data on consecutive MM patients who received novel ag
Autor:
Anita Kumar, Carla Casulo, Erel Joffe, Craig Moskowitz, John Gerecitano, Alison Moskowitz, Anas Younes, Pamela Drullinsky, Esther Drill, Morgan Choma, Clare Grieve, Ashlee Joseph, Leana Laraque, Dylan Schick, Andrew Zelenetz, Paul Hamlin
Publikováno v:
Leukemia & Lymphoma. 63:2889-2896
This study evaluated ofatumumab (Ofa), an anti-CD20 monoclonal antibody, alone or with bendamustine (Benda), in transplant-ineligible patients with mantle cell lymphoma. Low-risk patients received Ofa monotherapy. Non-responders received subsequent t
Autor:
Marlise Luskin
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:436-441
Acute lymphoblastic leukemia (ALL) is an aggressive blood cancer that affects both children and adults. Although the majority of children diagnosed with ALL are now cured and outcomes are improving for younger adults, older adults diagnosed with ALL
Autor:
Laura E. Fischer, Sebastian Stintzing, Ludwig Fischer von Weikersthal, Dominik P. Modest, Thomas Decker, Alexander Kiani, Florian Kaiser, Salah-Eddin Al-Batran, Tobias Heintges, Christian Lerchenmüller, Christoph Kahl, Gernot Seipelt, Frank Kullmann, Martina Stauch, Werner Scheithauer, Clemens Giessen-Jung, Jens Uhlig, Bettina Peuser, Claudio Denzlinger, Arndt Stahler, Lena Weiss, Kathrin Heinrich, Swantje Held, Andreas Jung, Thomas Kirchner, Volker Heinemann
Publikováno v:
British Journal of Cancer. 127:836-843
Summary Background The evidence on the efficacy of anticancer therapy is limited in older patients with metastatic colorectal cancer (mCRC). This retrospective analysis of phase III FIRE-3 trial assesses the efficacy of FOLFIRI plus either cetuximab